Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU

Zug, Switzerland– February 14, 2024– Galderma today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Applications for nemolizumab for the treatment of prurigo nodularis and for adolescents...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news